Hello I'm Raiyyan Tahsan
Brand Model and Executive

TC(1449).(12). ENT Department Case No (103):-Gross Left-Sided Deviated Nasal Septum (DNS) with Suspected Coexisting Allergic Rhinitis(1Prescription+0Report+0image)1133

Prescription attached:-

🟧 LIPU MED — FULL CLINICAL CASE REVIEW

Prescription Analysis | Clinical Working Diagnosis | MedEx Drug Review | Evidence-Based ENT Assessment

Proposed Website Publication Title:

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻĒāĻ°ā§āĻĻāĻž āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝāĻ­āĻžāĻŦ⧇ āĻŦāĻžāĻŽ āĻĻāĻŋāϕ⧇ āĻŦāĻžāρāĻ•āĻž (Gross Left-Sided DNS), āϝāĻžāϰ āϏāĻ™ā§āϗ⧇ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āύāĻžāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš (Allergic Rhinitis) āĻĨāĻžāĻ•āĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Attachments: 1 Prescription + 0 Investigation Reports + 0 Clinical Images

Overall diagnostic confidence: 0.86 for documented DNS; 0.65 for associated allergic rhinitis.

Clinical verification note: āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϞ⧇āĻ–āĻž āϤāĻĨā§āϝ, āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻĒāĻ°ā§āϝāĻŦ⧇āĻ•ā§āώāĻŖ āĻāĻŦāĻ‚ āφāĻŽāĻžāϰ clinical inference āφāϞāĻžāĻĻāĻžāĻ­āĻžāĻŦ⧇ āωāĻĒāĻ¸ā§āĻĨāĻžāĻĒāύ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤ āϰ⧋āĻ—ā§€āϕ⧇ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻ•āϰāĻž āĻšā§ŸāύāĻŋ āĻāĻŦāĻ‚ āϕ⧋āύ⧋ investigation report āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§ŸāύāĻŋāĨ¤ āϤāĻžāχ Allergic Rhinitis āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ diagnosis, āύāĻŋāĻļā§āϚāĻŋāϤ diagnosis āύ⧟āĨ¤ āĻ…āĻ¸ā§āĻĒāĻˇā§āϟ āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻž āĻ…āύ⧁āĻŽāĻžāύ āĻ•āϰ⧇ āύāĻŋāĻļā§āϚāĻŋāϤ āϤāĻĨā§āϝ āĻšāĻŋāϏ⧇āĻŦ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤


🟩 01. Website-Verified Case Number | āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāϟ āϝāĻžāϚāĻžāχāĻ•ā§ƒāϤ āϕ⧇āϏ āύāĻŽā§āĻŦāϰ

ā§¨ā§Ž āĻ…āĻ•ā§āĻŸā§‹āĻŦāϰ ⧍ā§Ļ⧍ā§Ŧ āϤāĻžāϰāĻŋāϖ⧇ raiyyantahsan.com Blog āϝāĻžāϚāĻžāχ āĻ•āϰ⧇ āĻĒāĻžāĻ“ā§ŸāĻž āϏāĻ°ā§āĻŦāĻļ⧇āώ āĻĒā§āϰāĻ•āĻžāĻļāĻŋāϤ āϕ⧇āϏ:

TC(1448).(01). Cardiology Department Case No (50)

āĻĒā§āϰāĻ•āĻžāĻļ⧇āϰ āϤāĻžāϰāĻŋāĻ–: 28 October 2026āĨ¤

ENT āĻŦāĻŋāĻ­āĻžāϗ⧇āϰ āϏāĻ°ā§āĻŦāĻļ⧇āώ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āϕ⧇āϏ:

TC(1437).(12). ENT Department Case No (102)

āĻĒā§āϰāĻ•āĻžāĻļ⧇āϰ āϤāĻžāϰāĻŋāĻ–: 26 October 2026āĨ¤

āϏ⧇āχ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āĻāχ āύāϤ⧁āύ āϕ⧇āϏ⧇āϰ āĻĒā§āϰāĻ¸ā§āϤāĻžāĻŦāĻŋāϤ āύāĻŽā§āĻŦāϰ:

TC(1449).(12). ENT Department Case No (103)

āĻāϟāĻŋ āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāĻŸā§‡āϰ āĻĻ⧃āĻļā§āϝāĻŽāĻžāύ numbering sequence āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϤ⧈āϰāĻŋ āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āύāĻŽā§āĻŦāϰ; āύāϤ⧁āύ āϕ⧇āϏāϟāĻŋ āĻāĻ–āύ⧋ āĻĒā§āϰāĻ•āĻžāĻļāĻŋāϤ āĻŦāĻž āϏāĻ‚āϰāĻ•ā§āώāĻŋāϤ āύ⧟āĨ¤

Confidence: 0.97


🟧 02. Patient Information | āϰ⧋āĻ—ā§€āϰ āϤāĻĨā§āϝ

ParameterPrescription FindingsConfidence
Patient Name — āϰ⧋āĻ—ā§€āϰ āύāĻžāĻŽāĻ—ā§‹āĻĒāĻ¨ā§€ā§ŸāϤāĻžāϰ āϜāĻ¨ā§āϝ āĻĒā§āϰāĻ•āĻžāĻļ āĻ•āϰāĻž āĻšā§ŸāύāĻŋ1.00
Age — āĻŦ⧟āϏ32 years0.98
Sex — āϞāĻŋāĻ™ā§āĻ—Male — āĻĒ⧁āϰ⧁āώ; āύāĻžāĻŽā§‡āϰ āφāϗ⧇ Mr. āϞ⧇āĻ–āĻž0.95
Prescription Date09 October 20260.95
DepartmentENT — āύāĻžāĻ•, āĻ•āĻžāύ āĻ“ āĻ—āϞāĻž āĻŦāĻŋāĻ­āĻžāĻ—1.00
ConsultantDr. Ratan Bikash Rudra0.99
SpecialtyENT Specialist & Surgeon0.99
Reports AvailableNone — āϕ⧋āύ⧋ āϰāĻŋāĻĒā§‹āĻ°ā§āϟ āϏāĻ‚āϝ⧁āĻ•ā§āϤ āύ⧇āχ1.00

🟩 03. C/C — Chief Complaints | āĻĒā§āϰāϧāĻžāύ āωāĻĒāϏāĻ°ā§āĻ—

Doctor’s Documentation

C/C: Not documented — āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻĒā§āϰāϧāĻžāύ āωāĻĒāϏāĻ°ā§āĻ— āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Confidence: 0.99

Clinically Inferred Complaints | āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āωāĻĒāϏāĻ°ā§āĻ—

āĻ“āώ⧁āϧ⧇āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻāĻŦāĻ‚ Gross DNS (Lt) āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰ⧇ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āωāĻĒāϏāĻ°ā§āĻ—āϗ⧁āϞ⧋:

Suspected C/CāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨConfidence
Nasal obstructionāύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻĨāĻžāĻ•āĻž āĻŦāĻž āĻļā§āĻŦāĻžāϏ āύāĻŋāϤ⧇ āĻŦāĻžāϧāĻž0.85
Predominantly left-sided nasal blockageāĻŦāĻžāĻŽ āύāĻžāϕ⧇ āϤ⧁āϞāύāĻžāĻŽā§‚āϞāĻ• āĻŦ⧇āĻļāĻŋ āĻŦāĻžāϧāĻž0.70
Nasal congestionāύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇āϰ āφāĻŦāϰāĻŖ āĻĢ⧁āϞ⧇ āύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻšāĻ“ā§ŸāĻž0.85
SneezingāĻšāĻžāρāϚāĻŋ0.55
RhinorrhoeaāύāĻžāĻ• āĻĻāĻŋā§Ÿā§‡ āĻĒāĻžāύāĻŋ āĻĒ⧜āĻž0.55
Nasal itchingāύāĻžāĻ• āϚ⧁āϞāĻ•āĻžāύ⧋0.50

Clinical interpretation — āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž:

Gross DNS-āĻāϰ āĻ•āĻžāϰāϪ⧇ āύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇āϰ āĻŦāĻžā§Ÿā§ āϚāϞāĻžāϚāϞ⧇āϰ āĻĒāĻĨ āϏāĻ‚āϕ⧁āϚāĻŋāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āĻ…āĻ¨ā§āϝāĻĻāĻŋāϕ⧇ Bilastine āĻ“ Montelukast āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻ•āĻžāϰāϪ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• allergic symptoms āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāϪ⧇āϰ āĻšā§‡āĻˇā§āϟāĻž āĻ•āϰāϛ⧇āύ āĻŦāϞ⧇ āĻŽāύ⧇ āĻšā§ŸāĨ¤

āϤāĻŦ⧇ āĻ“āώ⧁āϧ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡āϛ⧇ āĻŦāϞ⧇āχ āϰ⧋āĻ—ā§€āϰ āĻšāĻžāρāϚāĻŋ, āύāĻžāĻ• āϚ⧁āϞāĻ•āĻžāύ⧋ āĻŦāĻž āύāĻžāĻ• āĻĻāĻŋā§Ÿā§‡ āĻĒāĻžāύāĻŋ āĻĒ⧜āĻžāϰ āχāϤāĻŋāĻšāĻžāϏ āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤


🟧 04. History Assessment | āϰ⧋āĻ—ā§€āϰ āχāϤāĻŋāĻšāĻžāϏ

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āύāĻŋāĻšā§‡āϰ history-āϏāĻ‚āĻ•ā§āϰāĻžāĻ¨ā§āϤ āĻ•ā§āώ⧇āĻ¤ā§āϰāϗ⧁āϞ⧋āϰ āϕ⧋āύ⧋ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϤāĻĨā§āϝ āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāύāĻŋāĨ¤

HistoryEnglish MeaningāĻŦāĻžāĻ‚āϞāĻž āĻŦā§āϝāĻžāĻ–ā§āϝāĻžDocumentation
I/H — Illness HistoryPresent illness historyāĻŦāĻ°ā§āϤāĻŽāĻžāύ āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented
O/H — Occupational HistoryOccupational exposureāĻĒ⧇āĻļāĻžāĻ—āϤ āχāϤāĻŋāĻšāĻžāϏ, āϧ⧁āϞāĻžāĻŦāĻžāϞāĻŋ āĻŦāĻž āϰāĻžāϏāĻžā§ŸāύāĻŋāϕ⧇āϰ āϏāĻ‚āĻ¸ā§āĻĒāĻ°ā§āĻļNot documented
D/H — Drug HistoryPrevious/current medicine useāφāϗ⧇ āĻŦāĻž āĻŦāĻ°ā§āϤāĻŽāĻžāύ⧇ āĻŦā§āϝāĻŦāĻšā§ƒāϤ āĻ“āώ⧁āϧ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented
M/H — Medical HistoryPast or existing diseasesāĻĒā§‚āĻ°ā§āĻŦ⧇āϰ āĻ“ āĻŦāĻ°ā§āϤāĻŽāĻžāύ āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented
S/H — Surgical HistoryPrevious operationsāφāϗ⧇āϰ āĻ…āĻ¸ā§āĻ¤ā§āϰ⧋āĻĒāϚāĻžāϰ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented
F/H — Family HistoryFamilial disease historyāĻĒāĻžāϰāĻŋāĻŦāĻžāϰāĻŋāĻ• āϰ⧋āϗ⧇āϰ āχāϤāĻŋāĻšāĻžāϏNot documented
A/H — Allergy HistoryDrug/environmental allergyāĻ“āώ⧁āϧ āĻŦāĻž āĻĒāϰāĻŋāĻŦ⧇āĻļāĻ—āϤ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āχāϤāĻŋāĻšāĻžāϏNot documented
O/S/E — Other Systemic ExaminationAssessment of other body systemsāĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ…āĻ™ā§āĻ—āϤāĻ¨ā§āĻ¤ā§āϰ āĻĒāϰ⧀āĻ•ā§āώāĻžNot documented
O/G/E — Overall General ExaminationGeneral physical examinationāϏāĻžāĻŽāĻ—ā§āϰāĻŋāĻ• āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžNot documented

Confidence: 0.99

Important History to Obtain | āϝ⧇ āχāϤāĻŋāĻšāĻžāϏ āϜāĻžāύāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύ

āĻāχ āϰ⧋āϗ⧇āϰ āϏāĻ āĻŋāĻ• clinical assessment āĻ•āϰāϤ⧇ āϜāĻžāύāϤ⧇ āĻšāĻŦ⧇:

  1. āύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻ•āϤāĻĻāĻŋāύ āϧāϰ⧇?
  2. āĻŦāĻžāĻŽ āύāĻžāĻ• āĻŦ⧇āĻļāĻŋ āĻŦāĻ¨ā§āϧ āĻĨāĻžāϕ⧇, āύāĻžāĻ•āĻŋ āĻĻ⧁āχ āύāĻžāĻ•āχ?
  3. āĻšāĻžāρāϚāĻŋ, āύāĻžāĻ• āϚ⧁āϞāĻ•āĻžāύāĻŋ, āύāĻžāĻ• āĻĻāĻŋā§Ÿā§‡ āĻĒāĻžāύāĻŋ āĻĒ⧜āĻž āφāϛ⧇ āĻ•āĻŋ?
  4. āϰāĻžāϤ⧇ āύāĻžāĻ• āĻŦāĻ¨ā§āϧ, āĻŽā§āĻ– āĻĻāĻŋā§Ÿā§‡ āĻļā§āĻŦāĻžāϏ āύ⧇āĻ“ā§ŸāĻž āĻŦāĻž āύāĻžāĻ• āĻĄāĻžāĻ•āĻžāϰ āχāϤāĻŋāĻšāĻžāϏ āφāϛ⧇ āĻ•āĻŋ?
  5. āφāϗ⧇ āύāĻžāϕ⧇ āφāϘāĻžāϤ āĻĒā§‡ā§Ÿā§‡āĻ›āĻŋāϞ⧇āύ āĻ•āĻŋ?
  6. āφāϗ⧇ nasal spray āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āχāϤāĻŋāĻšāĻžāϏ āφāϛ⧇ āĻ•āĻŋ?
  7. Asthma, hypertension, glaucoma āĻŦāĻž psychiatric illness āφāϛ⧇ āĻ•āĻŋ?

Confidence: 0.95 — āĻāϗ⧁āϞ⧋ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ history questions, āϰ⧋āĻ—ā§€āϰ āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ history āύ⧟āĨ¤


🟩 05. O/E — On Examination | āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻž

Documented Finding

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ Advice āĻ…āĻ‚āĻļ⧇ āϞ⧇āĻ–āĻž:

Gross DNS (Lt)

āĻāϰ āĻĒā§‚āĻ°ā§āĻŖāϰ⧂āĻĒ:

Gross Deviated Nasal Septum — Left Side

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻŽāĻ§ā§āϝāĻŦāĻ°ā§āϤ⧀ āĻĒāĻ°ā§āĻĻāĻž āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝāĻ­āĻžāĻŦ⧇ āĻŦāĻžāĻŽ āĻĻāĻŋāϕ⧇ āĻŦāĻžāρāĻ•āĻžāĨ¤

āĻāϟāĻŋ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āĻĒā§āϰāϧāĻžāύ anatomical findingāĨ¤

Confidence: 0.98

O/E āĻ…āĻ‚āĻļ⧇ āφāϰāĻ“ āϛ⧋āϟ āĻāĻ•āϟāĻŋ āĻ…āĻ¸ā§āĻĒāĻˇā§āϟ āϞ⧇āĻ–āĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āϏ⧇āϟāĻŋ āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝāĻ­āĻžāĻŦ⧇ āĻĒāĻžāĻ ā§‹āĻĻā§āϧāĻžāϰ āĻ•āϰāĻž āϏāĻŽā§āĻ­āĻŦ āĻšā§ŸāύāĻŋāĨ¤

Clinical Meaning

Nasal Septum: āύāĻžāϕ⧇āϰ āĻĻ⧁āχ āĻĒāĻžāĻļāϕ⧇ āĻĒ⧃āĻĨāĻ• āĻ•āϰ⧇ āĻāĻŽāύ cartilage āĻ“ bone āĻĻā§āĻŦāĻžāϰāĻž āĻ—āĻ āĻŋāϤ āĻĒāĻ°ā§āĻĻāĻžāĨ¤

Septal Deviation: āĻāχ āĻĒāĻ°ā§āĻĻāĻž āĻŽāĻžāĻā§‡āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāύ āĻĨ⧇āϕ⧇ āĻāĻ•āĻĻāĻŋāϕ⧇ āϏāϰ⧇ āĻŦāĻž āĻŦāĻžāρāĻ•āĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āĻžāĨ¤

Gross DNS: āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻŦāĻ°ā§āĻŖāύāĻžā§Ÿ āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝ āĻŽāĻžāĻ¤ā§āϰāĻžāϰ septal deviationāĨ¤

āĻāϟāĻŋ āύāĻžāϕ⧇āϰ āĻŦāĻžā§Ÿā§ āϚāϞāĻžāϚāϞ⧇ āĻŦāĻžāϧāĻž āϏ⧃āĻˇā§āϟāĻŋ āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤ āϤāĻŦ⧇ āĻļ⧁āϧ⧁ anatomical deviation āĻĻ⧇āϖ⧇ āωāĻĒāϏāĻ°ā§āϗ⧇āϰ āϤ⧀āĻŦā§āϰāϤāĻž āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤


🟧 06. Investigations | āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āϝ⧇ āĻĒāϰ⧀āĻ•ā§āώāĻžāϗ⧁āϞ⧋ āĻĻāĻŋā§Ÿā§‡āϛ⧇āύ

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ Advice āĻ…āĻ‚āĻļ⧇ āύāĻŋāĻšā§‡āϰ āĻĒāϰ⧀āĻ•ā§āώāĻžāϗ⧁āϞ⧋ āĻĒ⧜āĻž āϝāĻžāĻšā§āϛ⧇āĨ¤

No.InvestigationāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨClinical PurposeConfidence
1CBCComplete Blood Count — āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āϰāĻ•ā§āϤāĻ•āĻŖāĻŋāĻ•āĻž āĻĒāϰ⧀āĻ•ā§āώāĻžAnaemia, platelet count āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ haematological abnormalities āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ0.99
2BTBleeding Time — āϰāĻ•ā§āϤāĻĒāĻžāϤ āĻŦāĻ¨ā§āϧ āĻšāϤ⧇ āϞāĻžāĻ—āĻž āϏāĻŽā§ŸāϐāϤāĻŋāĻšāĻžāϏāĻŋāĻ• bleeding assessment0.99
3CTClotting Time — āϰāĻ•ā§āϤ āϜāĻŽāĻžāϟ āĻŦāĻžāρāϧāĻžāϰ āϏāĻŽā§ŸāϐāϤāĻŋāĻšāĻžāϏāĻŋāĻ• clotting assessment0.99
4Blood UreaāϰāĻ•ā§āϤ⧇ āχāωāϰāĻŋ⧟āĻžāϰ āĻĒāϰāĻŋāĻŽāĻžāĻŖRenal assessment — āĻ•āĻŋāĻĄāύāĻŋ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ0.98
5RBSRandom Blood Sugar — āϝ⧇āϕ⧋āύ⧋ āϏāĻŽā§Ÿā§‡ āϰāĻ•ā§āϤ⧇āϰ āĻ—ā§āϞ⧁āϕ⧋āϜHyperglycaemia āĻŦāĻž diabetes screening0.99
6ECGElectrocardiogram — āĻšā§ƒāĻĻā§â€ŒāϝāĻ¨ā§āĻ¤ā§āϰ⧇āϰ āĻŦ⧈āĻĻā§āϝ⧁āϤāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžCardiac assessment0.99
7X-ray Chest PAāĻŦ⧁āϕ⧇āϰ āĻāĻ•ā§āϏ-āϰ⧇Selected cardiopulmonary assessment0.98
8X-ray PNS — OM ViewParanasal Sinuses X-ray, Occipitomental View — āϏāĻžāχāύāĻžāϏ⧇āϰ āĻāĻ•ā§āϏ-āϰ⧇āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ sinus pathology āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ0.96
9Blood GroupāϰāĻ•ā§āϤ⧇āϰ āĻ—ā§āϰ⧁āĻĒ āύāĻŋāĻ°ā§āϪ⧟āĻĒā§āĻ°ā§Ÿā§‹āϜāύ⧇ operative planning0.99
10HBsAgHepatitis B Surface Antigen — āĻšā§‡āĻĒāĻžāϟāĻžāχāϟāĻŋāϏ āĻŦāĻŋ āϏāĻ‚āĻ•ā§āϰāĻŽāϪ⧇āϰ āϚāĻŋāĻšā§āύHBV screening0.98

Important clarification — āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻŦā§āϝāĻžāĻ–ā§āϝāĻž:

āĻāχ āĻĒāϰ⧀āĻ•ā§āώāĻžāϗ⧁āϞ⧋āϰ āϤāĻžāϞāĻŋāĻ•āĻž āĻĻ⧇āϖ⧇ preoperative assessment-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āϤ⧈āϰāĻŋ āĻšā§ŸāĨ¤ āĻ…āĻ°ā§āĻĨāĻžā§Ž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• Septoplasty āĻŦāĻž āĻ…āĻ¨ā§āϝ āϕ⧋āύ⧋ ENT procedure āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰ⧇ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āύāĨ¤

āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āĻ¸ā§āĻĒāĻˇā§āϟāĻ­āĻžāĻŦ⧇ āĻ…āĻ¸ā§āĻ¤ā§āϰ⧋āĻĒāϚāĻžāϰ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Preoperative assessment inference confidence: 0.75.

Are all these investigations necessary?

āϏāĻŦ āĻĒāϰ⧀āĻ•ā§āώāĻž āĻĒā§āϰāĻ¤ā§āϝ⧇āĻ• DNS āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āĻŦāĻžāĻ§ā§āϝāϤāĻžāĻŽā§‚āϞāĻ• āύ⧟āĨ¤

NICE NG45 āĻ…āύ⧁āϝāĻžā§Ÿā§€ elective surgery-āĻāϰ āφāϗ⧇ ECG, chest X-ray, coagulation test āĻāĻŦāĻ‚ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻĒāϰ⧀āĻ•ā§āώāĻž āϰ⧋āĻ—ā§€āϰ āĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻ…āĻŦāĻ¸ā§āĻĨāĻž, āϏāĻšāϰ⧋āĻ— āĻ“ āĻ…āĻ¸ā§āĻ¤ā§āϰ⧋āĻĒāϚāĻžāϰ⧇āϰ āĻā§āρāĻ•āĻŋ āĻ…āύ⧁āϝāĻžā§Ÿā§€ āύāĻŋāĻ°ā§āĻŦāĻžāϚāύ āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

āĻŦāĻŋāĻļ⧇āώāϤ:

  • BT/CT: āφāϧ⧁āύāĻŋāĻ• preoperative bleeding-risk assessment-āĻāϰ āϜāĻ¨ā§āϝ āϏāĻžāϧāĻžāϰāĻŖāϤ āύāĻŋāĻ°ā§āĻ­āϰāϝ⧋āĻ—ā§āϝ screening test āύ⧟āĨ¤
  • Chest X-ray: āϏ⧁āĻ¸ā§āĻĨ āϰ⧋āĻ—ā§€āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āύāĻŋ⧟āĻŽāĻŋāϤ āĻ•āϰāĻž āϏ⧁āĻĒāĻžāϰāĻŋāĻļ āĻ•āϰāĻž āĻšā§Ÿ āύāĻžāĨ¤
  • ECG: āĻŦ⧟āϏ, cardiovascular history āĻ“ operative risk āĻŦāĻŋāĻŦ⧇āϚāύāĻžā§Ÿ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāĻž āĻšā§ŸāĨ¤
  • X-ray PNS: DNS āύāĻŋāĻ°ā§āĻŖā§Ÿā§‡āϰ āϜāĻ¨ā§āϝ āĻ…āĻĒāϰāĻŋāĻšāĻžāĻ°ā§āϝ āύ⧟; sinus disease āϏāĻ¨ā§āĻĻ⧇āĻš āĻšāϞ⧇ āωāĻĒāϝ⧁āĻ•ā§āϤ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

āĻāϗ⧁āϞ⧋ āĻŦāĻ°ā§āϤāĻŽāĻžāύ guideline āĻ…āύ⧁āϝāĻžā§Ÿā§€ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻŋāώ⧟āĨ¤

Confidence: 0.96


🟩 07. Doctor’s Diagnosis | āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āφāϞāĻžāĻĻāĻž Dx āϘāϰ āĻĒā§‚āϰāĻŖ āĻ•āϰāĻž āĻšā§ŸāύāĻŋāĨ¤

āϤāĻŦ⧇ Advice āĻ…āĻ‚āĻļ⧇ āĻ¸ā§āĻĒāĻˇā§āϟāĻ­āĻžāĻŦ⧇ āϞ⧇āĻ–āĻž āĻ°ā§Ÿā§‡āϛ⧇:

Gross DNS (Lt)

āĻ…āĻ°ā§āĻĨāĻžā§Ž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āĻŦāĻžāĻŽ āĻĻāĻŋāϕ⧇ āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝ Septal Deviation āĻļāύāĻžāĻ•ā§āϤ āĻ•āϰ⧇āϛ⧇āύāĨ¤

Doctor-documented diagnosis/finding: Gross Left-Sided Deviated Nasal Septum.

ICD-10-CM: J34.2

āĻ“āώ⧁āϧ⧇āϰ āĻ­āĻŋāĻ¤ā§āϤāĻŋāϤ⧇ Allergic Rhinitis āĻŦāĻŋāĻŦ⧇āϚāĻŋāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ āϏ⧇āϟāĻŋ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āĻ¸ā§āĻĒāĻˇā§āϟāĻ­āĻžāĻŦ⧇ āϞāĻŋāϖ⧇āϛ⧇āĻ¨â€”āĻāĻŽāύ āĻĒā§āϰāĻŽāĻžāĻŖ āύ⧇āχāĨ¤

Confidence: 0.98 for DNS; 0.65 for suspected associated allergic rhinitis.


🟧 08. My Clinical Working Diagnosis | āφāĻŽāĻžāϰ āĻ•ā§āϞāĻŋāύāĻŋāĻ•ā§āϝāĻžāϞ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Final Working Dx: Gross Left-Sided Deviated Nasal Septum (J34.2), with Suspected Coexisting Allergic Rhinitis (J30.9 — Unconfirmed).

āĻŦāĻžāĻ‚āϞāĻž āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

āĻŦāĻžāĻŽ āĻĻāĻŋāϕ⧇ āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝāĻ­āĻžāĻŦ⧇ āĻŦāĻžāρāĻ•āĻž āύāĻžāϕ⧇āϰ āĻĒāĻ°ā§āĻĻāĻž (DNS), āϝāĻžāϰ āϏāĻ™ā§āϗ⧇ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āύāĻžāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻĨāĻžāĻ•āĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

āĻāϟāĻŋ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āϝ⧁āĻ•ā§āϤāĻŋāϏāĻ‚āĻ—āϤ working diagnosis, āϤāĻŦ⧇ āϰ⧋āĻ—ā§€āϰ āωāĻĒāϏāĻ°ā§āĻ— āĻ“ āĻĒā§‚āĻ°ā§āĻŖ nasal examination āĻ›āĻžā§œāĻž associated rhinitis āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Diagnostic Confidence

Diagnostic ComponentConfidence
Documented gross left-sided DNS0.98
DNS contributing to nasal obstruction0.85
Associated allergic rhinitis0.65
Chronic rhinosinusitis0.35 — insufficient evidence
Planned septoplasty0.75 — inferred, not documented

🟩 09. Definition, Etiology & Pathophysiology

A. Deviated Nasal Septum (DNS)

Definition — āϏāĻ‚āĻœā§āĻžāĻž:

Deviation of the nasal septum from its normal midline position.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻŽāĻ§ā§āϝāĻŦāĻ°ā§āϤ⧀ āĻĒāĻ°ā§āĻĻāĻž āĻ¸ā§āĻŦāĻžāĻ­āĻžāĻŦāĻŋāĻ• āĻŽāĻžāĻā§‡āϰ āĻ…āĻŦāĻ¸ā§āĻĨāĻžāύ āĻĨ⧇āϕ⧇ āĻāĻ•āĻĻāĻŋāϕ⧇ āĻŦāĻžāρāĻ•āĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āĻžāĨ¤

Etiology — āϰ⧋āϗ⧇āϰ āĻ•āĻžāϰāĻŖ

  1. Congenital deviation: āϜāĻ¨ā§āĻŽāĻ—āϤāĻ­āĻžāĻŦ⧇ āύāĻžāϕ⧇āϰ āĻĒāĻ°ā§āĻĻāĻž āĻŦāĻžāρāĻ•āĻž āĻĨāĻžāĻ•āĻžāĨ¤
  2. Traumatic deviation: āύāĻžāϕ⧇ āφāϘāĻžāϤ⧇āϰ āĻ•āĻžāϰāϪ⧇ āĻĒāĻ°ā§āĻĻāĻž āϏāϰ⧇ āϝāĻžāĻ“ā§ŸāĻžāĨ¤
  3. Developmental deviation: āĻŽā§āĻ–āĻŽāĻŖā§āĻĄāϞ āĻ“ āύāĻžāϕ⧇āϰ āĻŦ⧃āĻĻā§āϧāĻŋāϰ āϏāĻŽā§Ÿ āĻ…āϏāĻŽ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύāĨ¤

Pathophysiology — āϰ⧋āĻ— āϏ⧃āĻˇā§āϟāĻŋāϰ āĻĒā§āϰāĻ•ā§āϰāĻŋ⧟āĻž

Septal deviation → Narrowing of nasal passage → Increased airway resistance → Nasal obstruction.

āĻŦāĻžāĻ‚āϞāĻžā§Ÿ:

āύāĻžāϕ⧇āϰ āĻĒāĻ°ā§āĻĻāĻž āĻŦāĻžāρāĻ•āĻž → āύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇ āϜāĻžā§ŸāĻ—āĻž āĻ•āĻŽā§‡ āϝāĻžāĻ“ā§ŸāĻž → āĻŦāĻžāϤāĻžāϏ āϚāϞāĻžāϚāϞ⧇ āĻŦāĻžāϧāĻž āĻŦ⧃āĻĻā§āϧāĻŋ → āύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻ…āύ⧁āĻ­ā§‚āϤ āĻšāĻ“ā§ŸāĻžāĨ¤

Confidence: 0.97

B. Allergic Rhinitis

Definition — āϏāĻ‚āĻœā§āĻžāĻž:

An IgE-mediated inflammatory disease of the nasal mucosa triggered by allergens.

āĻŦāĻžāĻ‚āϞāĻž: āϧ⧁āϞāĻžāĻŦāĻžāϞāĻŋ, āĻĒāϰāĻžāĻ—āϰ⧇āϪ⧁ āĻŦāĻž āĻ…āĻ¨ā§āϝ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āĻœā§‡āύ⧇āϰ āϏāĻ‚āĻ¸ā§āĻĒāĻ°ā§āĻļ⧇ āύāĻžāϕ⧇āϰ āϭ⧇āϤāϰ⧇āϰ āφāĻŦāϰāϪ⧇ IgE-mediated allergic inflammation āĻšāĻ“ā§ŸāĻžāĨ¤

Pathophysiology

Allergen exposure → IgE activation → Mast-cell activation → Histamine and leukotriene release → Nasal inflammation.

āĻŦāĻžāĻ‚āϞāĻžā§Ÿ:

āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āĻœā§‡āύ⧇āϰ āϏāĻ‚āĻ¸ā§āĻĒāĻ°ā§āĻļ → IgE āϏāĻ•ā§āϰāĻŋ⧟ āĻšāĻ“ā§ŸāĻž → Mast cell āĻĨ⧇āϕ⧇ histamine āĻ“ leukotriene āύāĻŋāσāϏāϰāĻŖ → āύāĻžāϕ⧇āϰ āφāĻŦāϰāĻŖ āĻĢ⧁āϞ⧇ āϝāĻžāĻ“ā§ŸāĻž, āĻšāĻžāρāϚāĻŋ, āĻĒāĻžāύāĻŋ āĻĒ⧜āĻž āĻ“ āύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻšāĻ“ā§ŸāĻžāĨ¤

Confidence: 0.98 for the mechanism; 0.65 for its presence in this patient.


🟧 10. Differential Diagnosis | āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āϰ⧋āĻ—

Differential DiagnosisāĻŦāĻžāĻ‚āϞāĻž āĻ…āĻ°ā§āĻĨClinical Consideration
Inferior turbinate hypertrophyāύāĻžāϕ⧇āϰ āύāĻŋāĻšā§‡āϰ āϟāĻžāϰāĻŦāĻŋāύ⧇āϟ āĻŦ⧜ āĻšāĻ“ā§ŸāĻžāύāĻžāĻ• āĻŦāĻ¨ā§āϧ⧇āϰ āĻ•āĻžāϰāĻŖ āĻšāϤ⧇ āĻĒāĻžāϰ⧇; āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āύ⧟
Non-allergic rhinitisāĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋ āĻ›āĻžā§œāĻž āύāĻžāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻšAllergic Rhinitis-āĻāϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ
Chronic rhinosinusitisāĻĻā§€āĻ°ā§āϘāĻŽā§‡ā§ŸāĻžāĻĻāĻŋ āύāĻžāĻ• āĻ“ āϏāĻžāχāύāĻžāϏ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻšāĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§Ÿ symptoms āĻ“ objective findings āĻ…āύ⧁āĻĒāĻ¸ā§āĻĨāĻŋāϤ
Nasal polyposisāύāĻžāϕ⧇āϰ āĻĒāϞāĻŋāĻĒEndoscopy āĻ›āĻžā§œāĻž āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟
Nasal valve dysfunctionāύāĻžāϕ⧇āϰ āĻĒā§āϰāĻŦ⧇āĻļāĻĒāĻĨ⧇āϰ āĻ•āĻžāĻ°ā§āϝāĻ—āϤ āϏāĻŽāĻ¸ā§āϝāĻžāĻļāĻžāϰ⧀āϰāĻŋāĻ• āĻĒāϰ⧀āĻ•ā§āώāĻžā§Ÿ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύāϝ⧋āĻ—ā§āϝ

Confidence: 0.95 for differential relevance; no alternative diagnosis is confirmed.


🟩 11. Original Prescription Drug Summary | āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āĻ“āώ⧁āϧ

No.BrandGenericMedEx Therapeutic ClassMain Purpose
1Biltin 20 mgBilastineAnti-histamineAllergic symptoms
2Lumona 10 mgMontelukast SodiumLeukotriene receptor antagonistsAllergic airway inflammation
3Rynex 0.05% Nasal DropOxymetazoline HydrochlorideNasal Decongestants & Other Nasal PreparationsTemporary relief of nasal congestion

āωāĻ˛ā§āϞāĻŋāĻ–āĻŋāϤ āϤāĻŋāύāϟāĻŋ brand āĻāĻŦāĻ‚ generic MedEx-āĻ āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āĻšā§Ÿā§‡āϛ⧇āĨ¤

Confidence: 0.97


🟧 12. Complete Drug Analysis — Medicine 1

1. Biltin 20 mg Tablet

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Bilastine 20 mg — āĻŦāĻŋāϞāĻžāĻ¸ā§āϟāĻŋāύ ⧍ā§Ļ āĻŽāĻŋ.āĻ—ā§āϰāĻž.

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Biltin — Eskayef Pharmaceuticals Ltd.

3. MedEx Alternate Brand — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Allertin 20 mg, Beltas 20 mg, Biltex 20 mg, Bilxen 20 mg.

āĻāĻ•āχ generic āĻ“ strength-āĻāϰ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ; āĻāĻ•āϏāĻ™ā§āϗ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āϤāĻžāϞāĻŋāĻ•āĻž āύ⧟āĨ¤

4. MedEx Therapeutic Class — āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻļā§āϰ⧇āĻŖāĻŋ

Anti-histamine — āĻ…ā§āϝāĻžāĻ¨ā§āϟāĻŋāĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύāĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Second-generation H1-receptor antagonist — āĻĻā§āĻŦāĻŋāĻ¤ā§€ā§Ÿ āĻĒā§āϰāϜāĻ¨ā§āĻŽā§‡āϰ H1 āĻšāĻŋāĻ¸ā§āϟāĻžāĻŽāĻŋāύ āϰāĻŋāϏ⧇āĻĒā§āϟāϰ āĻŦā§āϞāĻ•āĻžāϰāĨ¤

6. Use of Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Allergic rhinitis-āĻāϰ āωāĻĒāϏāĻ°ā§āĻ—, āĻŦāĻŋāĻļ⧇āώāϤ āĻšāĻžāρāϚāĻŋ, āύāĻžāĻ• āϚ⧁āϞāĻ•āĻžāύ⧋ āĻ“ āύāĻžāĻ• āĻĻāĻŋā§Ÿā§‡ āĻĒāĻžāύāĻŋ āĻĒ⧜āĻž āĻ•āĻŽāĻžāύ⧋āĨ¤

7. Why Prescribed in This Patient — āĻāχ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āϕ⧇āύ

DNS-āĻāϰ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ allergic symptoms āϏāĻ¨ā§āĻĻ⧇āĻš āĻ•āϰ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• āĻ“āώ⧁āϧāϟāĻŋ āĻĻāĻŋāϤ⧇ āĻĒāĻžāϰ⧇āύāĨ¤

Patient-specific confidence: 0.70.

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Headache, dizziness, somnolence, fatigue.

āĻŦāĻžāĻ‚āϞāĻž: āĻŽāĻžāĻĨāĻžāĻŦā§āϝāĻĨāĻž, āĻŽāĻžāĻĨāĻž āĻ˜ā§‹āϰāĻž, āϘ⧁āĻŽāϘ⧁āĻŽ āĻ­āĻžāĻŦ āĻ“ āĻ•ā§āϞāĻžāĻ¨ā§āϤāĻŋāĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ āĻŽā§‡āĻĄā§‡āĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Biltin 20 mg — MedEx

10. Unit Price, Strip Price & Other Strengths — āĻŽā§‚āĻ˛ā§āϝ āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻŽāĻžāĻ¤ā§āϰāĻž

Unit price: ā§ŗ15.00

Strip price: ā§ŗ150.00 (10 tablets)

Other available formulations:

  • Biltin 10 mg dispersible tablet
  • Biltin 12.5 mg/5 ml oral solution

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Selective H1-receptor blockade → Histamine effects reduced → Allergic symptoms decrease.

āĻŦāĻžāĻ‚āϞāĻž: Histamine-āĻāϰ āĻ•āĻžāϜ āĻŦāĻžāϧāĻžāĻ—ā§āϰāĻ¸ā§āϤ āĻ•āϰ⧇ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϰ āωāĻĒāϏāĻ°ā§āĻ— āĻ•āĻŽāĻžā§ŸāĨ¤

12. Drug Indications — āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻŋāϤ āϰ⧋āĻ—

Allergic rhinoconjunctivitis and urticaria.

āĻŦāĻžāĻ‚āϞāĻž: āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āύāĻžāĻ• āĻ“ āĻšā§‹āϖ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻāĻŦāĻ‚ āϚāĻžāĻ•āĻž āϚāĻžāĻ•āĻž āϚ⧁āϞāĻ•āĻžāύāĻŋāϝ⧁āĻ•ā§āϤ āĻĢ⧁āϏāĻ•ā§ā§œāĻŋāĨ¤

13. Drug Interactions & Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āĻĒā§āϰāϤāĻŋāύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž

Ketoconazole, erythromycin, cyclosporine āĻ“ diltiazem bilastine exposure āĻŦāĻžā§œāĻžāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Bilastine hypersensitivity āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻŋāώāĻŋāĻĻā§āϧāĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

āϘ⧁āĻŽāϘ⧁āĻŽ āĻ­āĻžāĻŦ āĻŦāĻž āĻŽāĻžāĻĨāĻž āĻ˜ā§‹āϰāĻž āĻšāϞ⧇ āĻ—āĻžā§œāĻŋ āϚāĻžāϞāĻžāύ⧋āϤ⧇ āϏāϤāĻ°ā§āĻ•āϤāĻž āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤ Severe renal impairment-āĻāϰ āϰ⧋āĻ—ā§€āϰ concomitant interacting drugs āĻŦāĻŋāĻļ⧇āώāĻ­āĻžāĻŦ⧇ āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āϏ⧇āĻŦāύāĻŦāĻŋāϧāĻŋ

Standard adult dose: 20 mg once daily.

āĻ–āĻžāϞāĻŋ āĻĒ⧇āĻŸā§‡, āĻ–āĻžāĻŦāĻžāϰ⧇āϰ āĻ…āĻ¨ā§āϤāϤ āĻāĻ• āϘāĻŖā§āϟāĻž āφāϗ⧇ āĻ…āĻĨāĻŦāĻž āĻĻ⧁āχ āϘāĻŖā§āϟāĻž āĻĒāϰ⧇ āĻ—ā§āϰāĻšāĻŖ āĻ•āϰāĻž āĻšā§ŸāĨ¤

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ ā§§ā§ĢāϟāĻŋ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ āϞ⧇āĻ–āĻž āφāϛ⧇ āĻŦāϞ⧇ āĻŽāύ⧇ āĻšāĻšā§āϛ⧇ āĻāĻŦāĻ‚ āĻĻāĻŋāύ⧇ āĻāĻ•āĻŦāĻžāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

Limited human pregnancy data; avoid unless clinically justified.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāĻ°ā§āϝāĻžāĻĒā§āϤ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āϤāĻĨā§āϝ āύāĻž āĻĨāĻžāĻ•āĻžā§Ÿ āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻžā§Ÿ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ›āĻžā§œāĻž āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§œāĻžāύ⧋ āωāϚāĻŋāϤāĨ¤ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύāĻ•āĻžāϞ⧇ āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

17. Other Combinations in MedEx — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻŦāĻŋāύ⧇āĻļāύ

āϝāĻžāϚāĻžāχāĻ•ā§ƒāϤ MedEx Bilastine āϤāĻžāϞāĻŋāĻ•āĻžā§Ÿ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ āϕ⧋āύ⧋ fixed-dose combination āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžā§ŸāύāĻŋāĨ¤ āĻŦāĻŋāĻ­āĻŋāĻ¨ā§āύ strength āĻ“ formulation āĻĒāĻžāĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤

Medicine data confidence: 0.97 | Why prescribed in this patient: 0.70.


🟧 13. Complete Drug Analysis — Medicine 2

2. Lumona 10 mg Tablet

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Montelukast Sodium 10 mg — āĻŽāĻ¨ā§āϟāĻŋāϞ⧁āĻ•āĻžāĻ¸ā§āϟ āϏ⧋āĻĄāĻŋ⧟āĻžāĻŽāĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Lumona — Eskayef Pharmaceuticals Ltd.

3. MedEx Alternate Brand — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Montair 10 mg, Montene 10 mg, Montex 10 mg.

4. MedEx Therapeutic Class — āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻļā§āϰ⧇āĻŖāĻŋ

Leukotriene receptor antagonists — āϞāĻŋāωāϕ⧋āĻŸā§āϰāĻŋā§Ÿā§‡āύ āϰāĻŋāϏ⧇āĻĒā§āϟāϰ āĻĒā§āϰāϤāĻŋāϰ⧋āϧāĻ•āĨ¤

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Cysteinyl leukotriene receptor-1 antagonist (CysLT1 antagonist).

āĻŦāĻžāĻ‚āϞāĻž: CysLT1 āϰāĻŋāϏ⧇āĻĒā§āϟāϰ⧇āϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āϰāĻŽ āĻŦāĻžāϧāĻžāĻ—ā§āϰāĻ¸ā§āϤāĻ•āĻžāϰ⧀ āĻ“āώ⧁āϧāĨ¤

6. Use of Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Asthma control āĻ“ āύāĻŋāĻ°ā§āĻŦāĻžāϚāĻŋāϤ āϰ⧋āĻ—ā§€āϰ Allergic Rhinitis symptoms āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāĻŖāĨ¤

7. Why Prescribed in This Patient — āĻāχ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āϕ⧇āύ

āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ allergic nasal inflammation āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāϪ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

DNS-āĻāϰ āĻŦāĻžāρāĻ•āĻž āĻĒāĻ°ā§āĻĻāĻž āĻāϟāĻŋ āϏ⧋āϜāĻž āĻ•āϰāϤ⧇ āĻĒāĻžāϰ⧇ āύāĻžāĨ¤

Patient-specific confidence: 0.70.

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Headache, abdominal pain, gastrointestinal discomfort, nausea.

āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻŋāϰāϞ āĻŦāĻž āϗ⧁āϰ⧁āϤāϰ āĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž: Sleep disturbance, nightmares, mood changes, depression, suicidal thoughts/actions.

āĻŦāĻžāĻ‚āϞāĻž: āϘ⧁āĻŽā§‡āϰ āϏāĻŽāĻ¸ā§āϝāĻž, āĻĻ⧁āσāĻ¸ā§āĻŦāĻĒā§āύ, āφāϚāϰāĻŖ āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāύ, āĻŦāĻŋāώāĻŖā§āĻŖāϤāĻž āĻāĻŦāĻ‚ āφāĻ¤ā§āĻŽāĻšāĻ¤ā§āϝāĻžāϰ āϚāĻŋāĻ¨ā§āϤāĻž āĻŦāĻž āφāϚāϰāϪ⧇āϰ āĻā§āρāĻ•āĻŋāĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ āĻŽā§‡āĻĄā§‡āĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Lumona 10 mg — MedEx

10. Unit Price, Strip Price & Other Strengths — āĻŽā§‚āĻ˛ā§āϝ āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻŽāĻžāĻ¤ā§āϰāĻž

Unit price: ā§ŗ12.00

Strip price: ā§ŗ168.00 (14 tablets)

Other forms:

  • 4 mg flash tablet
  • 5 mg flash tablet
  • 4 mg/3.5 gm oral granules

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Blocks CysLT1 receptors → Reduces leukotriene-mediated inflammatory effects.

āĻŦāĻžāĻ‚āϞāĻž: Leukotriene-āĻāϰ āĻ•āĻžāĻ°ā§āϝāĻ•ā§āϰāĻŽ āĻŦāĻžāϧāĻž āĻĻāĻŋā§Ÿā§‡ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āĻĒā§āϰāĻĻāĻžāĻšā§‡āϰ āĻ•āĻŋāϛ⧁ āĻĒā§āϰāĻ­āĻžāĻŦ āĻ•āĻŽāĻžā§ŸāĨ¤

12. Drug Indications — āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻŋāϤ āϰ⧋āĻ—

Asthma maintenance, exercise-induced bronchoconstriction prevention and selected allergic rhinitis.

āĻŦāĻžāĻ‚āϞāĻž: āĻšāĻžāρāĻĒāĻžāύāĻŋāϰ āĻĻā§€āĻ°ā§āϘāĻŽā§‡ā§ŸāĻžāĻĻāĻŋ āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāĻŖ, āĻŦā§āϝāĻžā§ŸāĻžāĻŽāϜāύāĻŋāϤ āĻļā§āĻŦāĻžāϏāύāĻžāϞāĻŋāϰ āϏāĻ‚āϕ⧋āϚāύ āĻĒā§āϰāϤāĻŋāϰ⧋āϧ āĻāĻŦāĻ‚ āύāĻŋāĻ°ā§āĻŦāĻžāϚāĻŋāϤ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāĻ• āϰāĻžāχāύāĻžāχāϟāĻŋāϏāĨ¤

13. Drug Interactions & Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āĻĒā§āϰāϤāĻŋāύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž

Phenobarbital āĻ“ rifampicin-āĻāϰ āĻŽāϤ⧋ enzyme inducer montelukast exposure āĻ•āĻŽāĻžāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Hypersensitivity āĻĨāĻžāĻ•āϞ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āύāĻŋāώāĻŋāĻĻā§āϧāĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

FDA Boxed Warning: Allergic Rhinitis-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻ…āĻ¨ā§āϝ āωāĻĒāϝ⧁āĻ•ā§āϤ allergy medicine āĻ•āĻžāĻ°ā§āϝāĻ•āϰ āύāĻž āĻšāϞ⧇ āĻŦāĻž āϏāĻšā§āϝ āύāĻž āĻšāϞ⧇ Montelukast āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

āĻāϟāĻŋ āϏāĻžāϧāĻžāϰāĻŖ mild allergic rhinitis-āĻāϰ first-choice medicine āύ⧟āĨ¤

FDA āϗ⧁āϰ⧁āϤāϰ neuropsychiatric adverse effects āϏāĻŽā§āĻĒāĻ°ā§āϕ⧇ āϏāϤāĻ°ā§āĻ• āĻ•āϰ⧇āϛ⧇āĨ¤ āύāϤ⧁āύ mood āĻŦāĻž behavioural symptoms āĻĻ⧇āĻ–āĻž āĻĻāĻŋāϞ⧇ āĻ“āώ⧁āϧ āĻŦāĻ¨ā§āϧ āĻ•āϰ⧇ āĻĻā§āϰ⧁āϤ prescriber-āĻāϰ āϏāĻ™ā§āϗ⧇ āϝ⧋āĻ—āĻžāϝ⧋āĻ— āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āϏ⧇āĻŦāύāĻŦāĻŋāϧāĻŋ

Adult standard dose: 10 mg once daily.

āĻ–āĻžāĻŦāĻžāϰ⧇āϰ āϏāĻ™ā§āϗ⧇ āĻŦāĻž āĻ›āĻžā§œāĻž āύ⧇āĻ“ā§ŸāĻž āϝāĻžā§ŸāĨ¤

āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ ā§Ŧā§ĻāϟāĻŋ āĻŸā§āϝāĻžāĻŦāϞ⧇āϟ āĻāĻŦāĻ‚ āĻĻāĻŋāύ⧇ āĻāĻ•āĻŦāĻžāϰ⧇āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļ āĻĒ⧜āĻž āϝāĻžāĻšā§āϛ⧇āĨ¤ āϤāĻŦ⧇ allergic rhinitis-āĻāϰ āϜāĻ¨ā§āϝ ā§Ŧā§Ļ āĻĻāĻŋāύ⧇āϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āφāϞāĻžāĻĻāĻžāĻ­āĻžāĻŦ⧇ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

Benefit-risk assessment āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

āĻŦāĻžāĻ‚āϞāĻž: āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύāĻ•āĻžāϞ⧇ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āĻāĻŦāĻ‚ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ āĻā§āρāĻ•āĻŋ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰ⧇ āϏāĻŋāĻĻā§āϧāĻžāĻ¨ā§āϤ āύāĻŋāϤ⧇ āĻšāĻŦ⧇āĨ¤

17. Other Combinations in MedEx — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻŦāĻŋāύ⧇āĻļāύ

āϝāĻžāϚāĻžāχāĻ•ā§ƒāϤ Lumona product page-āĻ fixed-dose combination āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āύ⧇āχāĨ¤ āϤāĻžāχ āϕ⧋āύ⧋ āύāĻŋāĻ°ā§āĻĻāĻŋāĻˇā§āϟ combined brand āϝāĻžāϚāĻžāχ āĻ›āĻžā§œāĻž āωāĻ˛ā§āϞ⧇āĻ– āĻ•āϰāĻž āĻšāĻšā§āϛ⧇ āύāĻžāĨ¤

Medicine data confidence: 0.97 | Patient-specific indication: 0.70.


🟧 14. Complete Drug Analysis — Medicine 3

3. Rynex 0.05% Nasal Drop

1. Generic Name — āĻœā§‡āύ⧇āϰāĻŋāĻ• āύāĻžāĻŽ

Oxymetazoline Hydrochloride 0.05% — āĻ…āĻ•ā§āϏāĻŋāĻŽā§‡āϟāĻžāĻœā§‹āϞāĻŋāύ āĻšāĻžāχāĻĄā§āϰ⧋āĻ•ā§āϞ⧋āϰāĻžāχāĻĄāĨ¤

2. Brand Name — āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ āύāĻžāĻŽ

Rynex — Incepta Pharmaceuticals Ltd.

3. MedEx Alternate Brand — āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻŦā§āĻ°ā§āϝāĻžāĻ¨ā§āĻĄ

Afrin, Oxynex, Oxymist, Oxyzolin — āĻāĻ•āχ generic-āĻāϰ āωāĻĒāϝ⧁āĻ•ā§āϤ nasal formulationsāĨ¤

4. MedEx Therapeutic Class — āĻĨ⧇āϰāĻžāĻĒāĻŋāωāϟāĻŋāĻ• āĻļā§āϰ⧇āĻŖāĻŋ

Nasal Anti-histamine Preparations, Nasal Decongestants & Other Nasal Preparations.

5. Pharmacological Class — āĻĢāĻžāĻ°ā§āĻŽāĻžāϕ⧋āϞāϜāĻŋāĻ•ā§āϝāĻžāϞ āĻļā§āϰ⧇āĻŖāĻŋ

Topical alpha-adrenergic agonist / sympathomimetic nasal decongestant.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āϰāĻ•ā§āϤāύāĻžāϞāĻŋ āϏāĻ‚āϕ⧁āϚāĻŋāϤāĻ•āĻžāϰ⧀ āĻ¸ā§āĻĨāĻžāĻ¨ā§€ā§Ÿ āĻ“āώ⧁āϧāĨ¤

6. Use of Purpose — āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇āϰ āωāĻĻā§āĻĻ⧇āĻļā§āϝ

Temporary relief of nasal congestion.

āĻŦāĻžāĻ‚āϞāĻž: āϏāĻžāĻŽā§ŸāĻŋāĻ•āĻ­āĻžāĻŦ⧇ āύāĻžāĻ• āĻŦāĻ¨ā§āϧ āĻ•āĻŽāĻžāύ⧋āĨ¤

7. Why Prescribed in This Patient — āĻāχ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āϕ⧇āύ

DNS-āĻāϰ āĻĒāĻžāĻļāĻžāĻĒāĻžāĻļāĻŋ nasal mucosal swelling āĻĨāĻžāĻ•āϞ⧇ āϏāĻžāĻŽā§ŸāĻŋāĻ•āĻ­āĻžāĻŦ⧇ airflow āωāĻ¨ā§āύāϤ āĻ•āϰāĻžāϰ āϜāĻ¨ā§āϝ āĻĻ⧇āĻ“ā§ŸāĻž āĻšā§Ÿā§‡ āĻĨāĻžāĻ•āϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

Patient-specific confidence: 0.85.

8. Side Effects — āĻĒāĻžāĻ°ā§āĻļā§āĻŦāĻĒā§āϰāϤāĻŋāĻ•ā§āϰāĻŋ⧟āĻž

Local irritation, burning sensation, dryness and sneezing.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇ āĻœā§āĻŦāĻžāϞāĻžāĻĒā§‹ā§œāĻž, āĻļ⧁āĻˇā§āĻ•āϤāĻž āĻ“ āĻšāĻžāρāϚāĻŋāĨ¤

Important: Prolonged use can cause rebound congestion or rhinitis medicamentosa.

āĻŦāĻžāĻ‚āϞāĻž: āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ āĻŦā§āϝāĻŦāĻšāĻžāϰ⧇ āĻ“āώ⧁āϧ⧇āϰ āĻ•āĻžāϰāϪ⧇āχ āύāĻžāĻ• āφāϰāĻ“ āĻŦ⧇āĻļāĻŋ āĻŦāĻ¨ā§āϧ āĻšā§Ÿā§‡ āϝāĻžāĻ“ā§ŸāĻžāϰ āϏāĻŽāĻ¸ā§āϝāĻž āϤ⧈āϰāĻŋ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤

9. Direct MedEx Link — āϏāϰāĻžāϏāϰāĻŋ āĻŽā§‡āĻĄā§‡āĻ•ā§āϏ āϞāĻŋāĻ‚āĻ•

Rynex 0.05% Nasal Drop — MedEx

10. Unit Price, Strip Price & Other Strengths — āĻŽā§‚āĻ˛ā§āϝ āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻŽāĻžāĻ¤ā§āϰāĻž

10 ml bottle: ā§ŗ45.00

Strip price āĻĒā§āϰāϝ⧋āĻœā§āϝ āύ⧟āĨ¤

Other formulations:

  • 0.025% nasal drop
  • 0.05% nasal spray

11. Mechanism of Action — āĻ•āĻžāĻ°ā§āϝāĻĒā§āϰāĻŖāĻžāϞāĻŋ

Alpha-adrenergic receptor activation → Nasal mucosal vasoconstriction → Reduced mucosal swelling.

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āϰāĻ•ā§āϤāύāĻžāϞāĻŋ āϏāĻ‚āϕ⧁āϚāĻŋāϤ āĻ•āϰ⧇ āĻĢā§‹āϞāĻž āĻ•āĻŽāĻžā§Ÿ āĻāĻŦāĻ‚ āϏāĻžāĻŽā§ŸāĻŋāĻ•āĻ­āĻžāĻŦ⧇ āĻļā§āĻŦāĻžāϏ āϚāϞāĻžāϚāϞ⧇āϰ āĻĒāĻĨ āĻĒā§āϰāĻļāĻ¸ā§āϤ āĻ•āϰ⧇āĨ¤

12. Drug Indications — āύāĻŋāĻ°ā§āĻĻ⧇āĻļāĻŋāϤ āϰ⧋āĻ—

Nasal congestion associated with rhinitis, upper respiratory allergy, common cold and selected sinonasal conditions.

13. Drug Interactions & Contraindications — āĻŽāĻŋāĻĨāĻ¸ā§āĻ•ā§āϰāĻŋ⧟āĻž āĻ“ āĻĒā§āϰāϤāĻŋāύāĻŋāĻ°ā§āĻĻ⧇āĻļāύāĻž

MAO inhibitors-āĻāϰ āϏāĻ™ā§āϗ⧇ āĻŦāĻž āϏ⧇āϗ⧁āϞ⧋ āĻŦāĻ¨ā§āϧ āĻ•āϰāĻžāϰ ā§§ā§Ē āĻĻāĻŋāύ⧇āϰ āĻŽāĻ§ā§āϝ⧇ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§œāĻžāϤ⧇ āĻšāĻŦ⧇āĨ¤

Cardiovascular disease, hyperthyroidism, angle-closure glaucoma āĻ“ āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ contraindications āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

14. Precautions & Warnings — āϏāϤāĻ°ā§āĻ•āϤāĻž

ARIA 2024–2025 guidance recommends against long-term intranasal decongestant use beyond five days.

āĻ…āĻ°ā§āĻĨāĻžā§Ž Oxymetazoline āύāĻŋ⧟āĻŽāĻŋāϤ āĻĻā§€āĻ°ā§āϘāĻĻāĻŋāύ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻ•āϰāĻž āωāϚāĻŋāϤ āύ⧟āĨ¤

āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āύāĻŋāĻšā§‡āϰ āύāĻŋāĻ°ā§āĻĻ⧇āĻļāϟāĻŋ āϏāĻŽā§āĻ­āĻŦāϤ āϞ⧇āĻ–āĻž āĻ°ā§Ÿā§‡āϛ⧇:

ā§Š āĻĢā§‹āρāϟāĻž × ā§Š āĻŦāĻžāϰ, āύāĻžāϕ⧇āĨ¤

āĻ•āĻŋāĻ¨ā§āϤ⧁ āĻšāĻžāϤ⧇āϰ āϞ⧇āĻ–āĻžāϰ āĻ•āĻžāϰāϪ⧇ duration āϏāĻŽā§āĻĒā§‚āĻ°ā§āĻŖ āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤

āĻāĻĻāĻŋāϕ⧇ MedEx-āĻ 0.05% nasal drops-āĻāϰ standard adult instructions āĻšāϞ⧋ āĻĒā§āϰāϤāĻŋ āύāĻžāϏāĻžāϰāĻ¨ā§āĻ§ā§āϰ⧇ ā§¨â€“ā§Š āĻĢā§‹āρāϟāĻž āĻĻāĻŋāύ⧇ āĻĻ⧁āχāĻŦāĻžāϰāĨ¤

āϏ⧁āϤāϰāĻžāĻ‚ āĻĻāĻŋāύ⧇ āϤāĻŋāύāĻŦāĻžāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻŦāĻž āĻĻā§€āĻ°ā§āϘāĻŽā§‡ā§ŸāĻžāĻĻāĻŋ duration āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āϏāĻ™ā§āϗ⧇ āϝāĻžāϚāĻžāχ āĻ•āϰāĻž āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖāĨ¤

15. Dosage & Administration — āĻŽāĻžāĻ¤ā§āϰāĻž āĻ“ āϏ⧇āĻŦāύāĻŦāĻŋāϧāĻŋ

MedEx adult dose: 2–3 drops in each nostril twice daily.

āĻ¸ā§āĻŦāĻ˛ā§āĻĒāĻŽā§‡ā§ŸāĻžāĻĻāĻŋ āĻŦā§āϝāĻŦāĻšāĻžāϰ; āϏāĻžāϧāĻžāϰāĻŖāϤ ā§Šâ€“ā§Ģ āĻĻāĻŋāύ⧇āϰ āĻŽāĻ§ā§āϝ⧇ āϏ⧀āĻŽāĻžāĻŦāĻĻā§āϧ āϰāĻžāĻ–āĻž āϝ⧁āĻ•ā§āϤāĻŋāϏāĻ‚āĻ—āϤ, āϝāĻĻāĻŋ treating clinician āĻ…āĻ¨ā§āϝāĻ­āĻžāĻŦ⧇ āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āύāĻž āĻ•āϰ⧇āύāĨ¤

16. Pregnancy & Lactation — āĻ—āĻ°ā§āĻ­āĻžāĻŦāĻ¸ā§āĻĨāĻž āĻ“ āĻ¸ā§āϤāĻ¨ā§āϝāĻĻāĻžāύ

Safety data limited; use requires medical assessment.

āĻŦāĻžāĻ‚āϞāĻž: āĻĒāĻ°ā§āϝāĻžāĻĒā§āϤ āύāĻŋāϰāĻžāĻĒāĻ¤ā§āϤāĻž āϤāĻĨā§āϝ āύ⧇āχ; āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ›āĻžā§œāĻž āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻā§œāĻžāύ⧋ āωāϚāĻŋāϤāĨ¤

17. Other Combinations in MedEx — āĻ…āĻ¨ā§āϝāĻžāĻ¨ā§āϝ āĻ•āĻŽā§āĻŦāĻŋāύ⧇āĻļāύ

MedEx-āĻ Oxymetazoline-āĻāϰ cream āĻ“ ophthalmic formulations-āĻ“ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āĻ°ā§Ÿā§‡āϛ⧇āĨ¤ āĻāϗ⧁āϞ⧋ āĻ…āĻ¨ā§āϝ formulation, nasal drop-āĻāϰ fixed-dose combination āύ⧟āĨ¤

Medicine data confidence: 0.98 | Prescription dosing interpretation: 0.65.


🟩 15. MedEx-Based Alternative Drug Options | āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇ āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āĻŦāĻŋāĻ•āĻ˛ā§āĻĒ āĻ“āώ⧁āϧ

Important: āύāĻŋāĻšā§‡āϰ āϤāĻžāϞāĻŋāĻ•āĻžāϟāĻŋ āĻāχ āϰ⧋āĻ—ā§€āϰ āϜāĻ¨ā§āϝ āύāϤ⧁āύ prescription āύ⧟āĨ¤ Allergic Rhinitis āĻ“ nasal congestion-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ āĻŦāĻžāĻ‚āϞāĻžāĻĻ⧇āĻļ⧇ MedEx-āϤāĻžāϞāĻŋāĻ•āĻžāϭ⧁āĻ•ā§āϤ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ therapeutic options āĻĻ⧇āĻ–āĻžāύ⧋ āĻšā§Ÿā§‡āϛ⧇āĨ¤

No.MedEx BrandGenericTherapeutic ClassSpecific Clinical Purpose
1Nasonex Nasal SprayMometasone FuroateNasal Steroid PreparationsAllergic inflammation āĻ“ congestion āĻ•āĻŽāĻžāύ⧋
2Fexofast 120 mgFexofenadineAnti-histamineāĻšāĻžāρāϚāĻŋ, āύāĻžāĻ• āϚ⧁āϞāĻ•āĻžāύ⧋, āĻĒāĻžāύāĻŋ āĻĒ⧜āĻž āĻ•āĻŽāĻžāύ⧋
3Montair 10 mgMontelukastLeukotriene receptor antagonistsāύāĻŋāĻ°ā§āĻŦāĻžāϚāĻŋāϤ allergic rhinitis/asthma āϰ⧋āĻ—ā§€
4NaSal 0.9% / Sodium Chloride brandsSodium ChlorideSaline Nasal PreparationNasal moisturisation āĻ“ mucus clearance
5Oxymetazoline Alternative BrandsOxymetazolineNasal DecongestantsāĻ¸ā§āĻŦāĻ˛ā§āĻĒāĻŽā§‡ā§ŸāĻžāĻĻāĻŋ nasal congestion relief

Clinical interpretation:

āĻŦāĻ°ā§āϤāĻŽāĻžāύ ARIA guidance āĻ…āύ⧁āϝāĻžā§Ÿā§€ persistent āĻŦāĻž bothersome allergic rhinitis-āĻāϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ intranasal corticosteroid āĻāĻ•āϟāĻŋ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ evidence-based treatment optionāĨ¤

āϤāĻŦ⧇ āĻāϟāĻŋ āύāĻžāϕ⧇āϰ āĻŦāĻžāρāĻ•āĻž āĻĒāĻ°ā§āĻĻāĻž āϏ⧋āϜāĻž āĻ•āϰ⧇ āύāĻžāĨ¤ Structural obstruction āĻāĻŦāĻ‚ mucosal inflammation—āĻĻ⧁āϟāĻŋ āĻĒ⧃āĻĨāĻ• therapeutic targetāĨ¤

Confidence: 0.96


🟧 16. Treatment Plan, Doctor’s Diagnosis Comparison & Prescription Demo

A. Doctor’s Dx vs My Working Dx

đŸŸĸ Similarities — āĻŽāĻŋāϞ

  • Doctor: Gross DNS (Lt).
  • My assessment: Gross Left-Sided Deviated Nasal Septum.
  • āĻĻ⧁āĻŸā§‹āϤ⧇āχ āύāĻžāϕ⧇āϰ āĻĒāĻ°ā§āĻĻāĻž āĻŦāĻžāĻŽ āĻĻāĻŋāϕ⧇ āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝāĻ­āĻžāĻŦ⧇ āĻŦāĻžāρāĻ•āĻž āĻĨāĻžāĻ•āĻžāϰ finding āĻāĻ•āχāĨ¤
  • Medications suggest that the physician may also be treating nasal allergic or inflammatory symptoms.

🟠 Differences — āĻ…āĻŽāĻŋāϞ

  • āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ• Allergic Rhinitis āĻ¸ā§āĻĒāĻˇā§āϟāĻ­āĻžāĻŦ⧇ āϞ⧇āϖ⧇āύāύāĻŋ; āφāĻŽāĻžāϰ assessment-āĻ āĻāϟāĻŋ suspected associated conditionāĨ¤
  • Nasal obstruction āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ C/C-āϤ⧇ āϞ⧇āĻ–āĻž āύ⧇āχ; āĻāϟāĻŋ āĻāĻ•āϟāĻŋ clinical inferenceāĨ¤
  • Septoplasty āĻĒāϰāĻŋāĻ•āĻ˛ā§āĻĒāύāĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āφāϛ⧇, āĻ•āĻŋāĻ¨ā§āϤ⧁ definitive surgical plan āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇ āϞ⧇āĻ–āĻž āύ⧇āχāĨ¤

Comparison Conclusion

The documented DNS finding and my primary working diagnosis are consistent.

āĻŦāĻžāĻ‚āϞāĻž: āϚāĻŋāĻ•āĻŋā§ŽāϏāϕ⧇āϰ āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āĻŽā§‚āϞ finding āĻāĻŦāĻ‚ āφāĻŽāĻžāϰ āĻĒā§āϰāϧāĻžāύ working diagnosis āĻāĻ•āχāĨ¤ āĻĒāĻžāĻ°ā§āĻĨāĻ•ā§āϝ āĻšāϞ⧋, āφāĻŽāĻŋ āϏāĻŽā§āĻ­āĻžāĻŦā§āϝ associated allergic rhinitis āϝ⧁āĻ•ā§āϤ āĻ•āϰ⧇āĻ›āĻŋ—āϝ⧇āϟāĻŋ āĻāĻ–āύ⧋ āύāĻŋāĻļā§āϚāĻŋāϤ āύ⧟āĨ¤

Comparison confidence: 0.96 for DNS agreement; 0.65 for suspected rhinitis.


B. Guideline-Based Management Plan | āϚāĻŋāĻ•āĻŋā§ŽāϏāĻž āĻĒāϰāĻŋāĻ•āĻ˛ā§āĻĒāύāĻž

Step 1 — Confirm symptom pattern: āύāĻžāĻ• āĻŦāĻ¨ā§āϧ⧇āϰ āϏāĻŽā§ŸāĻ•āĻžāϞ, āĻĒāĻžāĻļ, āϤ⧀āĻŦā§āϰāϤāĻž, āϘ⧁āĻŽā§‡āϰ āϏāĻŽāĻ¸ā§āϝāĻž āĻ“ allergy symptoms āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ āĻ•āϰāĻžāĨ¤

Step 2 — Complete nasal examination: Anterior rhinoscopy āĻ“ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ nasal endoscopy āĻ•āϰ⧇ septal deviation, turbinate hypertrophy, nasal polyps āĻ“ āĻ…āĻ¨ā§āϝ obstruction āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāĻžāĨ¤

Step 3 — Treat associated inflammation: Allergic Rhinitis āύāĻŋāĻļā§āϚāĻŋāϤ āĻšāϞ⧇ guideline-based intranasal treatment āĻŦāĻŋāĻŦ⧇āϚāύāĻž āĻ•āϰāĻžāĨ¤ Montelukast-āĻāϰ āĻĒā§āĻ°ā§Ÿā§‹āϜāĻ¨ā§€ā§ŸāϤāĻž āĻ“ safety āĻĒ⧁āύāĻ°ā§āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰāĻžāĨ¤

Step 4 — Review investigations: āφāϗ⧇ āĻĻ⧇āĻ“ā§ŸāĻž āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āĻĢāϞāĻžāĻĢāϞ, clinical indication āĻ“ operative risk āĻĒāĻ°ā§āϝāĻžāϞ⧋āϚāύāĻž āĻ•āϰāĻžāĨ¤

Step 5 — Assess need for surgery: Persistent troublesome nasal obstruction āĻĨāĻžāĻ•āϞ⧇ ENT specialist-āĻāϰ āĻŽāĻžāĻ§ā§āϝāĻŽā§‡ Septoplasty assessment āĻ•āϰāĻžāĨ¤

⧍ā§Ļā§¨ā§Š āϏāĻžāϞ⧇āϰ BMJ randomised trial-āĻ āωāĻĒāϝ⧁āĻ•ā§āϤ symptomatic septal deviation āϰ⧋āĻ—ā§€āĻĻ⧇āϰ āĻ•ā§āώ⧇āĻ¤ā§āϰ⧇ septoplasty medical management-āĻāϰ āϤ⧁āϞāύāĻžā§Ÿ āĻ­āĻžāϞ⧋ symptom improvement āĻĻ⧇āĻ–āĻŋā§Ÿā§‡āϛ⧇āĨ¤ āϤāĻŦ⧇ āĻāχ āϰ⧋āĻ—ā§€āϰ surgical eligibility āĻāĻ–āύ⧋ āĻĒā§āϰāϤāĻŋāĻˇā§āĻ āĻŋāϤ āύ⧟āĨ¤

Management confidence: 0.96


C. Clinical Prescription Demo | āĻļāĻŋāĻ•ā§āώāĻžāĻŽā§‚āϞāĻ• āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ āύāĻŽā§āύāĻž

This is an illustrative clinical record, not a replacement for an examination-based prescription.

ENT — Clinical Working Assessment

Patient: Adult male, 32 years

Source date: 09 October 2026

C/C: Not documented. Suspected nasal obstruction; requires history confirmation.

History: Not available.

O/E: Physician-documented gross DNS (Lt). Additional nasal findings not available.

Provisional Dx:

1. Gross Left-Sided Deviated Nasal Septum — J34.2

2. Suspected Coexisting Allergic Rhinitis — J30.9 (Unconfirmed)

Investigations ordered in source prescription: CBC, BT, CT, Blood Urea, RBS, ECG, Chest X-ray PA, PNS X-ray OM View, Blood Group, HBsAg.

Management: Review symptom severity, nasal examination, previously ordered investigations, treatment response and indications for septoplasty.

Medication reconciliation: Verify original Biltin, Lumona and Rynex directions. Review the indication and neuropsychiatric safety of montelukast; clarify oxymetazoline frequency and duration before continued use.

Follow-up: ENT review after examination and available results.

Final diagnosis status: Working assessment; not independently confirmed.


🟩 17. Final Clinical Assessment, Referral & References

Final Diagnosis for Website | āĻ“ā§Ÿā§‡āĻŦāϏāĻžāχāĻŸā§‡āϰ āϜāĻ¨ā§āϝ āϰ⧋āĻ—āύāĻŋāĻ°ā§āϪ⧟

Gross Left-Sided Deviated Nasal Septum with Suspected Coexisting Allergic Rhinitis

āĻŦāĻžāĻ‚āϞāĻž: āύāĻžāϕ⧇āϰ āĻĒāĻ°ā§āĻĻāĻž āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝāĻ­āĻžāĻŦ⧇ āĻŦāĻžāĻŽ āĻĻāĻŋāϕ⧇ āĻŦāĻžāρāĻ•āĻž, āϝāĻžāϰ āϏāĻ™ā§āϗ⧇ āĻ…ā§āϝāĻžāϞāĻžāĻ°ā§āϜāĻŋāϜāύāĻŋāϤ āύāĻžāϕ⧇āϰ āĻĒā§āϰāĻĻāĻžāĻš āĻĨāĻžāĻ•āĻžāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āĻ°ā§Ÿā§‡āϛ⧇āĨ¤

Recommended Department | āϕ⧋āύ āĻŦāĻŋāĻ­āĻžāϗ⧇ āϰ⧇āĻĢāĻžāϰ āĻ•āϰāĻŦ⧇āύ?

Primary referral: ENT / Otolaryngology — āύāĻžāĻ•, āĻ•āĻžāύ āĻ“ āĻ—āϞāĻž āĻŦāĻŋāĻļ⧇āώāĻœā§āĻžāĨ¤

āĻŦāĻŋāĻļ⧇āώāϤ āϝāĻŋāύāĻŋ nasal obstruction, septal deviation āĻ“ septoplasty āĻŽā§‚āĻ˛ā§āϝāĻžā§Ÿāύ āĻ•āϰ⧇āύāĨ¤

Allergic Rhinitis āϜāϟāĻŋāϞ āĻŦāĻž āϚāĻŋāĻ•āĻŋā§ŽāϏāĻžā§Ÿ āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāĻŖāĻšā§€āύ āĻšāϞ⧇ Allergy/Clinical Immunology specialist-āĻāϰ āĻŽāϤāĻžāĻŽāϤāĻ“ āĻŦāĻŋāĻŦ⧇āϚāύāĻžāϝ⧋āĻ—ā§āϝāĨ¤

Referral confidence: 0.98


Overview / Summary | āϏāĻžāϰāϏāĻ‚āĻ•ā§āώ⧇āĻĒ

āĻāχ āĻĒā§āϰ⧇āϏāĻ•ā§āϰāĻŋāĻĒāĻļāύ⧇āϰ āϏāĻŦāĻšā§‡ā§Ÿā§‡ āϗ⧁āϰ⧁āĻ¤ā§āĻŦāĻĒā§‚āĻ°ā§āĻŖ āĻŦāĻŋāώ⧟ āĻšāϞ⧋ Gross DNS (Lt)—āĻ…āĻ°ā§āĻĨāĻžā§Ž āύāĻžāϕ⧇āϰ āĻĒāĻ°ā§āĻĻāĻž āωāĻ˛ā§āϞ⧇āĻ–āϝ⧋āĻ—ā§āϝāĻ­āĻžāĻŦ⧇ āĻŦāĻžāĻŽ āĻĻāĻŋāϕ⧇ āĻŦāĻžāρāĻ•āĻž āĻĨāĻžāĻ•āĻžāϰ āϚāĻŋāĻ•āĻŋā§ŽāϏāĻ•-āύāĻĨāĻŋāϭ⧁āĻ•ā§āϤ findingāĨ¤

Biltin, Lumona āĻ“ Rynex-āĻāϰ āĻŦā§āϝāĻŦāĻšāĻžāϰ āĻĨ⧇āϕ⧇ associated allergic or inflammatory nasal symptoms āύāĻŋ⧟āĻ¨ā§āĻ¤ā§āϰāϪ⧇āϰ āĻšā§‡āĻˇā§āϟāĻž āĻ…āύ⧁āĻŽāĻžāύ āĻ•āϰāĻž āϝāĻžā§ŸāĨ¤ āĻ•āĻŋāĻ¨ā§āϤ⧁ āϕ⧇āĻŦāϞ āĻāχ āĻ“āώ⧁āϧ āĻĻ⧇āϖ⧇ Allergic Rhinitis āύāĻŋāĻļā§āϚāĻŋāϤ āĻ•āϰāĻž āϝāĻžā§Ÿ āύāĻžāĨ¤

āĻĒāϰ⧀āĻ•ā§āώāĻžāϰ āϤāĻžāϞāĻŋāĻ•āĻž preoperative preparation-āĻāϰ āϏāĻŽā§āĻ­āĻžāĻŦāύāĻž āϤ⧈āϰāĻŋ āĻ•āϰ⧇; āϤāĻŦ⧇ āĻ…āĻ¸ā§āĻ¤ā§āϰ⧋āĻĒāϚāĻžāϰ āύāĻŋāĻ°ā§āϧāĻžāϰāĻŋāϤ āĻšā§Ÿā§‡āĻ›ā§‡â€”āĻāĻŽāύ āĻĻāĻžāĻŦāĻŋ āĻ•āϰāĻž āϝāĻžāĻŦ⧇ āύāĻžāĨ¤

Overall confidence: 0.86 for the combined clinical interpretation.

Actionable Steps | āĻĒāϰāĻŦāĻ°ā§āϤ⧀ āĻ•āϰāĻŖā§€ā§Ÿ

āĻĒā§āϰāĻĨāĻŽā§‡ āĻĒā§‚āĻ°ā§āĻŖ nasal history, anterior rhinoscopy āĻāĻŦāĻ‚ āĻĒā§āĻ°ā§Ÿā§‹āϜāύ āĻ…āύ⧁āϝāĻžā§Ÿā§€ endoscopy āϏāĻŽā§āĻĒāĻ¨ā§āύ āĻ•āϰāϤ⧇ āĻšāĻŦ⧇āĨ¤ āϤāĻžāϰāĻĒāϰ investigation results āĻ“ symptom severity āĻ…āύ⧁āϝāĻžā§Ÿā§€ medical management āĻŦāύāĻžāĻŽ septoplasty āύāĻŋāĻ°ā§āϧāĻžāϰāĻŖ āĻ•āϰāĻž āωāϚāĻŋāϤāĨ¤ āĻŦāĻŋāĻļ⧇āώāĻ­āĻžāĻŦ⧇ Montelukast-āĻāϰ indication āĻāĻŦāĻ‚ Rynex-āĻāϰ dosing duration āϝāĻžāϚāĻžāχ āĻĒā§āĻ°ā§Ÿā§‹āϜāύāĨ¤

Confidence: 0.97


Reference List | āĻĒā§āϰāĻŽāĻžāĻŖāĻ­āĻŋāĻ¤ā§āϤāĻŋāĻ• āϤāĻĨā§āϝāϏ⧂āĻ¤ā§āϰ

Authoritative Textbooks

  1. Dhingra PL, Dhingra S. Diseases of Ear, Nose and Throat & Head and Neck Surgery. Nasal septum, nasal obstruction and rhinitis-related chapters. āϏāĻ‚āĻ¸ā§āĻ•āϰāĻŖāϭ⧇āĻĻ⧇ chapter āĻ“ page āĻĒāϰāĻŋāĻŦāĻ°ā§āϤāĻŋāϤ āĻšāϤ⧇ āĻĒāĻžāϰ⧇āĨ¤
  2. Flint PW, et al. Cummings Otolaryngology: Head and Neck Surgery. 7th edition. Elsevier; 2021. Nasal obstruction and septal surgery-related chapters.
  3. Harrison’s Principles of Internal Medicine. 22nd edition. McGraw Hill; 2025. Allergy and clinical immunology-related sections.

International Guidelines

  1. ARIA–EAACI Guidelines, 2024–2025 Revision. Intranasal treatment recommendations for allergic rhinitis.
  2. American Academy of Otolaryngology–Head and Neck Surgery. Clinical Indicators: Septoplasty; 2014.
  3. NICE NG45. Routine Preoperative Tests for Elective Surgery; 2016.
  4. US FDA. Boxed Warning on Montelukast: Serious Mental Health Side Effects; 2020.

Peer-Reviewed Research with Verified DOI

  1. Bousquet J, et al. Allergic Rhinitis and Its Impact on Asthma (ARIA)–EAACI Guidelines—2024–2025 Revision: Part I. Allergy. 2026;81(4):954–976. DOI: 10.1111/all.70131
  2. Carrie S, et al. Clinical effectiveness of septoplasty versus medical management for nasal airways obstruction: multicentre, open-label, randomised controlled trial. BMJ. 2023;383:e075445. DOI: 10.1136/bmj-2023-075445

Verified Drug References — MedEx Bangladesh

  1. Biltin 20 mg — Bilastine
  2. Lumona 10 mg — Montelukast Sodium
  3. Rynex 0.05% Nasal Drop — Oxymetazoline

Author: Md.Rafiqul Islam Lipu

Date: Wednesday, 28 October 2026

Time: 01:06 PM (Bangladesh Standard Time, UTC+06:00)

Publication Series: LIPU MED — Clinical Case Review

Case Reference: TC(1449).(12). ENT Department Case No (103)

Clinical status: Evidence-based educational working assessment; definitive diagnosis requires direct patient evaluation.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top